Exhibit 99.1

GLAUKOS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(in thousands, except per share amounts)


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2024		2023		2024		2023
Net sales	$	95,690	$	80,399	$	181,312	$	154,298
Cost of sales		22,550		20,103		42,808		38,174
Gross profit		73,140		60,296		138,504		116,124
Operating expenses:
Selling, general and administrative		66,188		53,137		128,163		106,787
Research and development		34,426		33,234		65,152		68,405
Acquired in-process research and development		2,500		3,000		14,229		3,000
Total operating expenses		103,114		89,371		207,544		178,192
Loss from operations		(29,974)		(29,075)		(69,040)		(62,068)
Non-operating expense:
Interest income		2,828		1,894		5,911		3,542
Interest expense		(3,354)		(3,399)		(6,804)		(6,807)
Charges associated with convertible senior notes		(18,012)		—		(18,012)		—
Other expense, net		(1,701)		(1,797)		(2,729)		(1,269)
Total non-operating expense		(20,239)		(3,302)		(21,634)		(4,534)
Loss before taxes		(50,213)		(32,377)		(90,674)		(66,602)
Income tax provision		331		435		708		836
Net loss	$	(50,544)	$	(32,812)	$	(91,382)	$	(67,438)

Basic and diluted net loss per share	$	(1.00)	$	(0.68)	$	(1.82)	$	(1.40)

Weighted average shares used to compute basic and diluted net loss per share		50,715		48,281		50,169		48,082

GLAUKOS CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except par values)


	June 30,		December 31,
	2024		2023
	(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	68,075	$	93,467
Short-term investments		193,589		201,964
Accounts receivable, net		51,217		39,850
Inventory		56,480		41,986
Prepaid expenses and other current assets		14,420		18,194
Total current assets		383,781		395,461
Restricted cash		4,733		5,856
Property and equipment, net		100,230		103,212
Operating lease right-of-use assets		26,430		27,146
Finance lease right-of-use asset		42,970		44,180
Intangible assets, net		275,673		282,956
Goodwill		66,134		66,134
Deposits and other assets		19,725		15,469
Total assets	$	919,676	$	940,414

Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$	11,560	$	13,440
Accrued liabilities		58,523		60,574
Total current liabilities		70,083		74,014
Convertible senior notes		56,692		282,773
Operating lease liability		29,912		30,427
Finance lease liability		70,009		70,538
Deferred tax liability, net		7,142		7,144
Other liabilities		20,678		13,752
Total liabilities		254,516		478,648

Stockholders' equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued or outstanding		—		—
Common stock, $0.001 par value; 150,000 shares authorized; 54,852 and 49,148 shares issued and 54,824 and 49,120 shares outstanding as of June 30, 2024 and December 31, 2023, respectively		55		49
Additional paid-in capital		1,353,495		1,059,751
Accumulated other comprehensive income		2,191		1,165
Accumulated deficit		(690,449)		(599,067)
Less treasury stock (28 shares as of June 30, 2024 and December 31, 2023)		(132)		(132)
Total stockholders’ equity		665,160		461,766
Total liabilities and stockholders' equity	$	919,676	$	940,414

GLAUKOS CORPORATION

GAAP to Non-GAAP Reconciliations

(in thousands, except per share amounts and percentage data)

(unaudited)

	Q2 2024									Q2 2023
	GAAP			Adjustments			Non-GAAP			GAAP			Adjustments			Non-GAAP

Cost of sales	$	22,550		$	(5,523)	(a)	$	17,027		$	20,103		$	(5,523)	(a)	$	14,580

Gross Margin		76.4	%		5.8	%		82.2	%		75.0	%		6.9	%		81.9	%

Operating expenses:
Selling, general and administrative	$	66,188		$	(705)	(b)	$	65,483		$	53,137		$	(705)	(b)	$	52,432

Loss from operations	$	(29,974)		$	6,228		$	(23,746)		$	(29,075)		$	6,228		$	(22,847)

Non-operating expense:
Charges associated with convertible senior notes	$	(18,012)		$	18,012	(c)	$	—		$	—		$	—		$	—

Net loss	$	(50,544)		$	24,240	(d)	$	(26,304)		$	(32,812)		$	6,228	(d)	$	(26,584)

Basic and diluted net loss per share	$	(1.00)		$	0.48		$	(0.52)		$	(0.68)		$	0.13		$	(0.55)

(a)	Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of $5.5 million.

(b)	Avedro acquisition-related amortization expense of customer relationship intangible assets of $0.7 million.

(c)	Expenses associated with the exchange of convertible senior notes, consisting of a non-cash inducement charge of $17.4 million and direct transaction costs of $0.6 million.

(d)	Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the U.S., the tax effect is $0 given the Company's U.S. taxable loss positions in both 2024 and 2023.

GLAUKOS CORPORATION

GAAP to Non-GAAP Reconciliations

(in thousands, except per share amounts and percentage data)

(unaudited)

	Year-to-Date Q2 2024									Year-to-Date Q2 2023
	GAAP			Adjustments			Non-GAAP			GAAP			Adjustments			Non-GAAP
Cost of sales	$	42,808		$	(11,046)	(a)	$	31,762		$	38,174		$	(11,046)	(a)	$	27,128

Gross Margin		76.4	%		6.1	%		82.5	%		75.3	%		7.1	%		82.4	%

Operating expenses:
Selling, general and administrative	$	128,163		$	(1,410)	(b)	$	126,753		$	106,787		$	(1,410)	(b)	$	105,377

Loss from operations	$	(69,040)		$	12,456		$	(56,584)		$	(62,068)		$	12,456		$	(49,612)

Non-operating expense:
Charges associated with convertible senior notes	$	(18,012)		$	18,012	(c)	$	—		$	—		$	—		$	—

Net loss	$	(91,382)		$	30,468	(d)	$	(60,914)		$	(67,438)		$	12,456	(d)	$	(54,982)

Basic and diluted net loss per share	$	(1.82)		$	0.61		$	(1.21)		$	(1.40)		$	0.26		$	(1.14)

(a)	Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of $11.0 million.

(b)	Avedro acquisition-related amortization expense of customer relationship intangible assets of $1.4 million.

(c)	Expenses associated with the exchange of convertible senior notes, consisting of a non-cash inducement charge of $17.4 million and direct transaction costs of $0.6 million.

(d)	Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the U.S., the tax effect is $0 given the Company's U.S. taxable loss positions in both 2024 and 2023.


Reported Sales vs. Prior Periods (in thousands)
							Year-over-Year Percent Change					Quarter-over-Quarter Percent Change
	2Q 2024		2Q 2023		1Q 2024		Reported		Operations (1)		Currency (2)	Reported		Operations (1)		Currency (2)

International Glaucoma	$	26,131	$	22,305	$	25,238	17.1	%	21.0	%	(3.9%)	3.5	%	5.1	%	(1.6%)

Total Net Sales	$	95,690	$	80,399	$	85,622	19.0	%	20.1	%	(1.1%)	11.8	%	12.2	%	(0.4%)

(1)

Operational growth excludes the effect of translational currency

(2)

Calculated by converting the current period numbers using the prior period’s average foreign exchange rates